|
|
 |
Free IGF-I IRMA Test | | | General Information | |
| Vendor | | Diagnostic Systems Laboratories, Inc. | | Item | | Free IGF-I IRMA Test | | Catalog Number | | DSL-9400 | | Size | | 100 tubes | | Range | | 6, 0.15 - 20 ng/mL | | Sample Type | | Serum, Plasma | | Regulatory Status | | For In Vitro Diagnostic Use | | Discipline | | Coated Tube IRMA | | Sensitivity | | 0.03 ng/mL | | Incubation Time | | 3 hrs on shaker at RT | | Pricing |  | Inquire | | Financing | | To finance this purchase click here (U.S. customers only) |
| | Product Description | |
| Insulin-like growth factor I (IGF-I or somatomedin C) is a 7.6 kDa peptide produced primarily in the liver. It acts as a potent mitogen of cellular proliferation, exerting its actions by binding to specific cell-surface receptors. In the circulation, IGF-I is bound to IGF-binding proteins (IGFBPs), which appear to regulate the actions of IGF-I by modulating the interaction of IGF-I with the Type 1 IGF receptor. The majority of IGF-I in blood is bound to a high molecular weight ternary complex with IGFBP-3 and ALS [1,2]. A smaller proportion of IGF-I circulates in association with other IGFBPs [2], and less than 5% is unbound or free IGF-I. It is believed that free IGF-I represents the biologically active fraction of IGF-I [3].
IGF-I concentrations in serum are dependent on age and sex. Levels increase from birth through mid-puberty, then decline to relatively stable levels during adult life, with a modest decrease in elderly people. In addition, IGF-I levels remain relatively stable throughout the day [4,5]. IGF-I is also dependent on growth hormone (GH) secretion, with IGF-I mediating many of the actions of GH [6]. In GH deficiency, malnutrition [4] and GH-receptor deficiency [7], serum IGF-I levels are low. Conversely, in acromegaly (GH excess) serum IGF-I levels are elevated [4,6]. Measurement of IGF-I levels in serum is a useful diagnostic test for the clinical evaluation of GH-related disorders. Additionally, there is a growing research interest in the role of IGF-I in cancer risk assessment [8.9].
- Baxter RC, et al. J Biol Chem 264:11843-11848, 1989.
- Rechler M. Vit Horm 47:1-114, 1993.
- Juul A. et al. J Clin Endocrinol Metab 82: 2497-2502, 1997.
- Lee PDK & Rosenfeld RG. Pediatrician 14:154-161, 1987.
- Rosenfeld RG, et al. J. Pediatr 109:428-433, 1986.
- Daughaday E & Rotwein P. Endocrin Rev 10:68-91, 1989.
- Guevara-Aguirre J, et al. J Clin Endocrinol Metab 76:417-423, 1993.
- Chan JM, et al. Science 279:563-566, 1998.
- Hankinson SE, et al. The Lancet 351:1373-1374, 1998.
| |
|
 |
| Diagnostic Systems Laboratories, Inc. | | Customer Service: (800) 231-7970 | | Web site: http://www.dslabs.com | | Please mention Medcompare.com when you contact the vendor. |
| NOTE: Medcompare disclaims any information on this site. The information found on Medcompare (Drug Guide, Product Listings and otherwise) is intended for use by medical professionals. This information is not intended to replace the information, advice or instructions from a medical doctor. Pricing information is approximate, actual prices may vary. |
|
|
